Pacira(PCRX)

Search documents
PharmaCorp Files 2024 Year End Audited Financial Statements and MD&A
Globenewswire· 2025-04-22 17:15
Group 1 - PharmaCorp Rx Inc. has filed its audited financial statements and associated MD&A for the year ended December 31, 2024, on SEDAR+ [1] - The company operates three PharmaChoice bannered pharmacies in Canada and plans to acquire more as they become available [2] - PharmaCorp intends to acquire independently owned non-PharmaChoice Canada bannered pharmacies and operate them under the PharmaChoice Canada banner [2] Group 2 - PharmaCorp shares are traded on the TSX Venture Exchange under the symbol PCRX [2]
Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again
ZACKS· 2025-04-21 17:15
Core Insights - Pacira (PCRX) has consistently surpassed earnings estimates, averaging a 7.77% beat over the last two quarters [1] - In the last reported quarter, Pacira achieved earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.86 per share by 5.81% [2] - The previous quarter also saw Pacira outperforming expectations, with actual earnings of $0.79 per share against an estimate of $0.72 per share, resulting in a surprise of 9.72% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Pacira, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [4] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [5] - Pacira currently has an Earnings ESP of +12.06%, suggesting analysts are optimistic about the company's earnings prospects [7] Importance of Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [6] - A positive Earnings ESP combined with a Zacks Rank 3 indicates a potential earnings beat, while a negative value reduces predictive power but does not guarantee a miss [7] - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the likelihood of successful investment decisions [8]
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
Prnewswire· 2025-04-21 12:15
Core Viewpoint - DOMA Perpetual believes that Pacira BioSciences' stock is undervalued, presenting an opportunity for the company to execute its largest buyback in history [1][4]. Group 1: Capital Allocation and Shareholder Value - DOMA Perpetual views the new capital allocation announcement as a strong commitment from Pacira's Board to enhance shareholder value [2]. - The combination of a $300 million share repurchase program and a focus on increasing pre-tax net income margins is expected to strengthen shareholder returns [3]. - The management is now tasked with effectively executing these initiatives to realize their potential [3]. Group 2: Growth and Financial Position - DOMA Perpetual is encouraged by Pacira's steps towards long-term value creation, indicating a period of rapid growth for the company [4]. - The new capital allocation priorities reflect Pacira's considerable momentum in scaling earnings and free cash flow, allowing for meaningful capital returns to shareholders while still investing in growth [4]. - The stock is considered undervalued relative to its historical average and the anticipated multi-year growth cycle ahead [4].
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
Newsfilter· 2025-04-17 21:00
Core Viewpoint - Pacira BioSciences, Inc. is committed to enhancing shareholder value through strategic actions aimed at optimizing operational performance and creating sustainable, long-term value for shareholders [1][3] Group 1: Strategic Initiatives - The company has made significant progress in advancing its 5x30 strategy to transition into an innovative biopharmaceutical organization and aims to become a leader in musculoskeletal pain and related areas by 2030 [2] - The Board of Directors has authorized a share repurchase program of up to $300 million, reinforcing confidence in the company's growth strategy and commitment to shareholder value [5] - The company is focused on enhancing operational efficiency and aims to improve gross margins by 5 percentage points over 2024 [5] Group 2: Product Portfolio - Pacira offers three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and iovera®º, which are designed to manage pain without opioids [4] - The company is advancing the development of PCRX-201, a novel locally administered gene therapy aimed at treating prevalent diseases like osteoarthritis [4] Group 3: Future Outlook - Pacira plans to treat more than 3 million patients annually and aims for a double-digit compounded annual growth rate for revenue [5] - The company is expanding its clinical pipeline with five novel programs in development and establishing five new partnerships, including pipeline and commercial agreements [5]
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Seeking Alpha· 2025-04-09 14:03
Core Insights - Pacira BioSciences, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on non-opioid pain management therapies, with key products including Exparel, Zilretta, and iovera [1] Group 1 - The NOPAIN Act is expected to provide a favorable secular tailwind for Pacira BioSciences, enhancing the market for non-opioid pain management solutions [1]
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Newsfilter· 2025-04-07 20:30
Core Viewpoint - Pacira BioSciences has settled litigation with Fresenius Kabi and others regarding patents for EXPAREL, allowing Fresenius to sell a volume-limited amount of generic bupivacaine liposome injectable suspension starting in early 2030, with unlimited sales permitted from 2039 [1][3][4]. Group 1: Settlement Details - The settlement includes Consent Judgments that prevent Fresenius from marketing the generic product before the expiration of the relevant patents, except as specified in the settlement [2]. - Fresenius will receive a license to manufacture and sell a limited volume of the generic product starting in early 2030, with the last of Pacira's patents expiring on July 2, 2044 [3]. - The volume-limited sales will start at a high-single-digit percentage of total U.S. market volumes, increasing to the low thirties by 2033, and reaching a maximum in the high thirties for the final three years of the agreement [4]. Group 2: Company Strategy and Products - Pacira emphasizes confidence in its intellectual property portfolio and aims to focus on advancing its 5x30 strategy to enhance its leadership in musculoskeletal pain management [5]. - The company offers three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera, and is developing PCRX-201, a gene therapy for osteoarthritis [6].
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
Newsfilter· 2025-04-03 12:00
Core Viewpoint - Pacira BioSciences has initiated the Phase 2 ASCEND study for PCRX-201, a novel gene therapy aimed at treating knee osteoarthritis by enhancing the production of the anti-inflammatory protein IL-1Ra [1][2][8] Company Overview - Pacira BioSciences is focused on delivering innovative, non-opioid pain therapies, with a commitment to transforming patient lives [1][10] - The company has three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera° [10] Study Design - The ASCEND study is a two-part, multicenter trial involving approximately 135 patients aged 45 to 80 with painful knee osteoarthritis [3][5] - Patients will be randomized into treatment groups receiving either PCRX-201 or saline, with two different doses being evaluated [4][6] Drug Details - PCRX-201 is based on a proprietary high-capacity adenovirus vector platform, designed for local administration to target chronic inflammation in knee osteoarthritis [7][12] - The therapy aims to provide sustained pain relief and improve function, with previous Phase 1 results showing effects lasting up to two years [2][8] Regulatory Designations - PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Advanced Therapy Medicinal Products (ATMP) designation from the EMA, indicating its potential to address significant unmet medical needs [8] Manufacturing and Scalability - The drug product for Part B of the study will utilize a newly developed suspension-based batch manufacturing process, aimed at commercial scale-up [5] - The high-capacity adenovirus vector platform allows for efficient gene delivery and the potential for cost-effective production of therapies [12]
Pharmacorp Announces Agreement to Acquire Pre-1954 Charter Company in Ontario
Globenewswire· 2025-04-03 11:00
SASKATOON, Saskatchewan, April 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a definitive share purchase agreement with an arm’s length vendor (the “Vendor”) dated April 1, 2025 to acquire a 100% interest in a pre-1954 charter company (the “Charter Company”) in Ontario, Canada (the “Acquisition”). The Corporation has agreed to purchase the Charter Company for $2,090,000, which will be paid using cash on hand ( ...
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Globenewswire· 2025-04-01 12:00
CONTACT: Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long- acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic ...
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
ZACKS· 2025-03-21 17:40
Shares of Pacira BioSciences (PCRX) have surged 66.8% in the past six months against the industry’s decline of 8.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe.Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.PCRX Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchExparel’s Performance Fuels PCRX GrowthExparel, Pacira’s flagship pain-management pro ...